专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006076561A1 PROCESS FOR PREPARING AMORPHOUS VALSARTAN 审中-公开
标题翻译：制备非晶态瓦斯坦的方法
公开(公告)号：WO2006076561A1
公开(公告)日：2006-07-20
申请号：PCT/US2006/001203
申请日：2006-01-11
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , KOLTAI, Tamas , MALACHI, Omer , SASSON, Nisim , GOLD, Amir
发明人： KOLTAI, Tamas , MALACHI, Omer , SASSON, Nisim , GOLD, Amir
IPC分类号： C07D257/04
CPC分类号： C07D257/04
摘要： The present invention provides a process for the preparation of amorphous valsartan.
摘要翻译：本发明提供了制备无定形缬沙坦的方法。

2. 发明申请

WO2007059325A2 DRYING METHODS OF MONTELUKAST SODIUM BY AZEOTROPIC REMOVAL OF THE SOLVENT 审中-公开
标题翻译：分子蒸馏法去除蒙脱石钠的干燥方法
公开(公告)号：WO2007059325A2
公开(公告)日：2007-05-24
申请号：PCT/US2006/044764
申请日：2006-11-16
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , KOR-SADE, Ilan , GOLD, Amir , SINGER, Claude , DEE-NOOR, Ziv , MALACHI, Omer
发明人： KOR-SADE, Ilan , GOLD, Amir , SINGER, Claude , DEE-NOOR, Ziv , MALACHI, Omer
CPC分类号： C07D215/18
摘要： The invention encompasses amorphous montelukast sodium having less than about 50 ppm heptane or less than about 100 ppm hexane, less than about 150 ppm toluene, and less than about 2500 ppm C 1 -C 5 alcohols, as well as processes for its preparation.
摘要翻译：本发明包括无定形孟鲁司特钠，其具有小于约50ppm的庚烷或小于约100ppm的己烷，小于约150ppm的甲苯和小于约2500ppm的C 1 / sub > -C5醇，以及其制备方法。

3. 发明申请

WO2009042179A1 CRYSTALLINE FORMS OF IBANDRONIC ACID AND PROCESSESES FOR THE PREPARATION THEREOF 审中-公开
标题翻译： IBANDRONIC酸的结晶形式及其制备方法
公开(公告)号：WO2009042179A1
公开(公告)日：2009-04-02
申请号：PCT/US2008/011126
申请日：2008-09-24
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , SINGER, Claude , AVHAR-MAYDAN, Sharon , KOLTAI, Tamas , GOLD, Amir
发明人： SINGER, Claude , AVHAR-MAYDAN, Sharon , KOLTAI, Tamas , GOLD, Amir
IPC分类号： C07F9/38
CPC分类号： C07F9/386 , C07F9/3873
摘要： A crystalline ibandronic acid characterized by data selected from the group consisting of at least one of a powder x-ray diffraction pattern having peaks at about 4.1, 12.3 and 13.4 ± 0.2 degrees two-theta and at least two more peaks selected from the group consisting of: 8.2, 11.3, 16.2 and 16.9 and 20.8 ± 0.2 degrees two-theta, and by a powder X-ray diffraction pattern depicted in Figure 1 is provided. Also provided is a crystalline ibandronic acid characterized by data selected from the group consisting of at least one of a powder x-ray diffraction pattern having peaks at about peaks at about 5.2, 11.7, and 18.7 ± 0.2 degrees two- theta and at least two more peaks selected from the group consisting of: 5.8, 10.1, 12.0, 17.1, and 20.0 ± 0.2 degrees two-theta and a powder X-ray diffraction pattern as depicted in Figure 2. Methods of preparing the crystalline forms are also provided.
摘要翻译：一种结晶伊班膦酸，其特征在于选自以下的数据：至少一种粉末X射线衍射图，其具有在约4.1,12.3和13.4±0.2度2-θ以及至少两个以上的峰，所述峰选自：8.2,11.3,16.2和16.9和20.8±0.2度2-θ，以及图1所示的粉末X射线衍射图。还提供了结晶伊班膦酸，其特征在于选自以下的数据：粉末x射线衍射图案中的至少一种，其在约5.2,11.7和18.7±0.2度2θ处的峰处具有峰值，并且至少两个更多选自5.8,10.1,12.0,17.1和20.0±0.2度2-θ的峰和如图2所示的粉末X射线衍射图。还提供了制备晶体形式的方法。

4. 发明申请

WO2006086779A1 AMORPHOUS ZIPRASIDONE MESYLATE 审中-公开
公开(公告)号：WO2006086779A1
公开(公告)日：2006-08-17
申请号：PCT/US2006/005114
申请日：2006-02-13
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , ARONHIME, Judith , MENDELOVICI, Marioara , LEVI, Sigalit , MAINFELD, Alex , GOLD, Amir
发明人： ARONHIME, Judith , MENDELOVICI, Marioara , LEVI, Sigalit , MAINFELD, Alex , GOLD, Amir
CPC分类号： C07D417/12
摘要： Provided is amorphous form of ziprasidone mesylate and process for its preparation. Also provided is a process for preparing ziprasidone mesylate dihydrate needle crystals.
摘要翻译：提供了无定形形式的齐拉西酮甲磺酸盐及其制备方法。还提供了制备齐拉沙酮甲磺酸盐二水合物针状晶体的方法。

5. 发明申请

WO2006086787A1 PROCESS OF PREPARING ZIPRASIDONE MESYLATE 审中-公开
标题翻译：制备ZIPRASIDONE MESYLATE的方法
公开(公告)号：WO2006086787A1
公开(公告)日：2006-08-17
申请号：PCT/US2006/005188
申请日：2006-02-13
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , MAINFELD, Alex , GOLD, Amir , MENDELOVICI, Marioara
发明人： MAINFELD, Alex , GOLD, Amir , MENDELOVICI, Marioara
IPC分类号： C07D417/12
CPC分类号： C07D417/14 , C07D417/12
摘要： In one embodiment, the present invention provides a process of preparing amorphou ziprasidone mesylate comprising the step of spray-drying a solution of ziprasidone mesylat in a solvent selected from a group consisting of: C 1 -C 5 alcohols, C 2 -C 8 ethers, glacial acetic acid and mixtures thereof with water, using an outlet temperature of above about 90°C Preferably the inlet temperature is above the outlet temperature. In another embodiment, the present invention provides a process of preparing ziprasidone mesylate crystal form characterized by X-ray powder diffraction peaks at 11.7, 17.3, 23.5, 24.2, and 25.2 degrees two-theta, ± 0.2 degrees two-theta (herein defined as Form I) comprising the step of spray-drying a solution of ziprasidone mesylate in a solvent selected from a group consisting of: glacial acetic acid and mixtures thereof with C 2 -C 8 ethers using an outlet temperature of above about 70°C, and collecting the obtained Form I. Preferably the inlet temperature is above the outlet temperature. In another embodiment, the present invention provides a process of preparing ziprasidone mesylate crystal form characterized by X-ray powder diffraction peaks at 17.1. 18.7, 23.8, and 24.4 degrees two-theta, ±0.2 degrees two-theta (herein defined as Form VIII) comprising the step of spray-drying a solution of ziprasidone mesylate in C 1 -C 5 alcohols and mixtures thereof with water using an outlet temperature of from about above 45°C to about 70°C. Preferably the inlet temperature is above the outlet temperature.
摘要翻译：在一个实施方案中，本发明提供了一种制备甲氧基缩甲硅烷基缩水甘油酯的方法，包括以下步骤：将齐拉西酮甲磺酸盐溶液在选自以下的溶剂中喷雾干燥的步骤：C 1 -C 3 > 5个醇，C 2 -C 8 - 醚，冰乙酸及其与水的混合物，使用出口温度高于约90℃。优选地，入口温度高于出口温度。在另一个实施方案中，本发明提供了制备齐拉西酮甲磺酸盐晶体形式的方法，其特征在于在11.7,17.3,23.5,24.2和25.2度2θ，±0.2度2θ（本文定义为形式I）包括将齐拉西酮甲磺酸酯溶液在选自以下的溶剂中喷雾干燥的步骤：冰醋酸及其与C 2 -C 8的混合物 >使用出口温度高于约70℃的醚，并收集所获得的形式I.优选地，入口温度高于出口温度。在另一个实施方案中，本发明提供了制备在17.1℃下以X射线粉末衍射峰为特征的齐拉西酮甲磺酸盐晶体形式的方法。 18.7,28.8和24.4度2θ，±0.2度2θ（本文定义为形式VIII），包括将齐拉西酮甲磺酸酯溶液在C 1 -C 3 > 5℃的醇及其与水的混合物，其出口温度为约45℃至约70℃。优选地，入口温度高于出口温度。

6. 发明申请

WO2008106217A1 PREPARATION OF GABAPENTIN BY LIQUID-LIQUID EXTRACTION 审中-公开
标题翻译：通过液体萃取制备加巴丁胺
公开(公告)号：WO2008106217A1
公开(公告)日：2008-09-04
申请号：PCT/US2008/002696
申请日：2008-02-28
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , DEE-NOOR, Ziv , GOLD, Amir
发明人： DEE-NOOR, Ziv , GOLD, Amir
IPC分类号： C07C227/16 , C07C229/28
CPC分类号： C07C227/16 , C07C229/28
摘要： This invention relates to an efficient process for converting gabapentin hydrochloride salt to gabapentin by liquid-liquid extraction using a counter-current extraction method.
摘要翻译：本发明涉及使用逆流萃取方法通过液 - 液萃取将加巴喷丁盐酸盐转化为加巴喷丁的有效方法。

7. 发明申请

WO2006081515A3 DULOXETINE HYDROCHLORIDE POLYMORPHS 审中-公开
公开(公告)号：WO2006081515A3
公开(公告)日：2006-08-03
申请号：PCT/US2006/003126
申请日：2006-01-27
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , INI, Santiago , SHMUELI, Yaron , KOLTAI, Tamás , GOLD, Amir
发明人： INI, Santiago , SHMUELI, Yaron , KOLTAI, Tamás , GOLD, Amir
IPC分类号： C07D333/20 , A61K31/381
摘要： A crystalline form of duloxetine hydrochloride, pharmaceutical compositions of the crystalline form of duloxetine hydrochloride, and methods of preparing the crystalline form of duloxetine hydrochloride are provided.

8. 发明申请

WO2010008493A2 PROCESSES FOR PREPARING HIGH PURITY AZA CYCLOHEXAPEPTIDES 审中-公开
标题翻译：制备高纯度AZA环糊精的方法
公开(公告)号：WO2010008493A2
公开(公告)日：2010-01-21
申请号：PCT/US2009/003839
申请日：2009-06-25
申请人： TEVA GYÓGYSZERGYÁR ZÁRTKÖRÜEN MÜKÖDÖ RÉSZVÉNYTÁRSASÁG , TEVA PHARMACEUTICALS USA, INC. , EIDELMAN, Chaim , TOVI, Avi , ALON, Hagai , PIROGOV, Vitali , GELFOND, Adelina , NEMETHNE RACZ, Csilla , KORODI, Ferenc , KOVACS, Piroska , GOLD, Amir , RUDINSKI, Alexander
发明人： EIDELMAN, Chaim , TOVI, Avi , ALON, Hagai , PIROGOV, Vitali , GELFOND, Adelina , NEMETHNE RACZ, Csilla , KORODI, Ferenc , KOVACS, Piroska , GOLD, Amir , RUDINSKI, Alexander
IPC分类号： C07K7/56 , A61P31/10
CPC分类号： C07K7/56
摘要： Provided are processes for the preparation and purification of high purity aza cyclohexapep tides.
摘要翻译：提供了用于制备和纯化高纯度氮杂环己烷潮汐的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式